In one paragraphArticle in Innate immunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Aizhen YangCyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Fourth Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-8067-4771 Yue LuCyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Fourth Hospital of Soochow University, Suzhou, China.ORCID 0009-0008-8865-9227 Xiaofeng YanCyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Fourth Hospital of Soochow University, Suzhou, China.ORCID 0009-0001-3814-9957 Meinan PengCyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Fourth Hospital of Soochow University, Suzhou, China.ORCID 0009-0002-0069-7648 Miao JiangCyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Fourth Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-4929-4885 Yi WuCyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Fourth Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-5116-9266 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
High-molecular-weight kininogen (HK) is known to bind lipopolysaccharides (LPS) with high affinity and serves as a crucial LPS carrier in circulation, supporting endotoxemia. However, its role in host defense against Gram-negative bacterial infection remains unclear. Here we demonstrate that HK directly binds to
Indexed as
Escherichia coliEscherichia coli InfectionsKininogen, High-Molecular-WeightNeutrophilsSepsisAnimalsCytokinesHumansImmunity, InnateKininogensLipopolysaccharidesMiceMice, Inbred C57BLMice, KnockoutReactive Oxygen SpeciesCytokinesKininogen, High-Molecular-WeightKininogensKNG1 protein, humanLipopolysaccharidesReactive Oxygen Speciescontact systemEscherichia coliHigh-molecular-weight kininogenlipopolysaccharidessepsis
Identifiers
PMID41400834
PMCPMC12708997
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390